Clinical Trial Update: PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for PEGPH20 with gemcitabine and nab-paclitaxel in pancreatic ductal adenocarcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)
• PEGPH20 (pegylated hyaluronidase)

Snippet

Sponsor: Andrew Ko | Conditions: Adenocarcinoma | Phase 2 | Status: TERMINATED | Results posted: 2020-01-02